Candel Therapeutics (CADL) Operating Income: 2020-2024
Historic Operating Income for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to -$33.4 million.
- Candel Therapeutics' Operating Income fell 27.37% to -$10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$38.4 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of -$33.4 million for FY2024, which is 13.08% up from last year.
- Per Candel Therapeutics' latest filing, its Operating Income stood at -$33.4 million for FY2024, which was up 13.08% from -$38.4 million recorded in FY2023.
- Over the past 5 years, Candel Therapeutics' Operating Income peaked at -$13.8 million during FY2020, and registered a low of -$38.4 million during FY2023.
- Moreover, its 3-year median value for Operating Income was -$34.7 million (2022), whereas its average is -$35.5 million.
- Per our database at Business Quant, Candel Therapeutics' Operating Income plummeted by 86.29% in 2021 and then increased by 13.08% in 2024.
- Candel Therapeutics' Operating Income (Yearly) stood at -$13.8 million in 2020, then plummeted by 86.29% to -$25.7 million in 2021, then slumped by 34.97% to -$34.7 million in 2022, then dropped by 10.57% to -$38.4 million in 2023, then grew by 13.08% to -$33.4 million in 2024.